Edgestream Partners L.P. Purchases New Holdings in ICU Medical, Inc. $ICUI

Edgestream Partners L.P. acquired a new position in ICU Medical, Inc. (NASDAQ:ICUI) during the first quarter, Holdings Channel.com reports. The institutional investor acquired 7,474 shares of the medical instruments supplier’s stock, valued at approximately $965,000.

Several other institutional investors have also added to or reduced their stakes in ICUI. Janus Henderson Group PLC boosted its position in shares of ICU Medical by 3.9% during the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock valued at $345,607,000 after buying an additional 99,256 shares during the period. Amundi raised its holdings in shares of ICU Medical by 39.9% in the first quarter. Amundi now owns 6,475 shares of the medical instruments supplier’s stock worth $836,000 after buying an additional 1,848 shares during the period. California State Teachers Retirement System raised its holdings in shares of ICU Medical by 25.2% in the first quarter. California State Teachers Retirement System now owns 27,512 shares of the medical instruments supplier’s stock worth $3,553,000 after buying an additional 5,536 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of ICU Medical by 1,394.0% in the first quarter. The Manufacturers Life Insurance Company now owns 170,418 shares of the medical instruments supplier’s stock worth $22,009,000 after buying an additional 159,011 shares during the period. Finally, Lombard Odier Asset Management USA Corp bought a new stake in shares of ICU Medical during the 1st quarter worth approximately $323,000. Institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Performance

Shares of NASDAQ:ICUI opened at $171.96 on Wednesday. The firm’s 50 day simple moving average is $149.55 and its 200-day simple moving average is $140.57. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. ICU Medical, Inc. has a one year low of $107.00 and a one year high of $176.27. The firm has a market cap of $4.30 billion, a PE ratio of 92.95, a price-to-earnings-growth ratio of 2.42 and a beta of 0.74.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The firm had revenue of $525.77 million during the quarter, compared to analyst estimates of $520.65 million. During the same quarter in the previous year, the business earned $1.72 earnings per share. ICU Medical’s quarterly revenue was down 12.3% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, equities analysts predict that ICU Medical, Inc. will post 6.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ICUI shares. KeyCorp boosted their price objective on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a report on Tuesday, July 21st. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Piper Sandler decreased their target price on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Needham & Company LLC raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 27th. Finally, Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, ICU Medical has a consensus rating of “Moderate Buy” and an average price target of $172.00.

Insiders Place Their Bets

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the sale, the director directly owned 7,960 shares of the company’s stock, valued at $978,363.60. The trade was a 23.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the company’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the sale, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.